Rapamycin for APOE4 Carriers: 400 Patients, Zero Dementia (Expert Q&A Recap)

The strongest real-world signal comes from Dr. Alan Green's clinical cohort of roughly 1,500 rapamycin patients, 300 to 400 of whom were APOE4 carriers mostly in their 60s through 80s. Over an average follow-up of five years (prime time for cognitive decline), not a single carrier received a dementia diagnosis. While these patients were affluent, educated, and health-conscious (factors that lower baseline dementia risk on their own), Dr. Grant Fraser's take is that zero diagnoses out of 300 to 400 high-risk carriers makes it very unlikely rapamycin played no role. This is observational clinical data, not a randomized trial, so it should be weighed accordingly.

No, according to Dr. Grant Fraser. Compounded rapamycin capsules are destroyed in the stomach before the drug can be absorbed, meaning patients likely receive only about one-third of the stated dose. His recommendation is to use only coated, FDA-approved rapamycin tablets, which are also cheaper at roughly 65 cents per milligram at CVS with a GoodRx coupon. Several Phoenix members on the expert Q&A call were taking compounded capsules and did not know they were being underdosed. If you are currently on a compounded formulation, discuss switching to coated tablets with a physician experienced in rapamycin prescribing.

Dosing must be personalized through blood-level testing, not based on fixed weekly amounts. Dr. Grant Fraser shared that he has two patients of the same weight, gender, and similar age where one needs 3 mg weekly and the other needs 18 mg to hit target blood levels, a 6x difference. He targets a blood rapamycin level of 3 ng/mL measured at 50 hours post-dose. Without blood-level monitoring, you are either underdosed and wasting money or overdosed and risking metabolic side effects like glucose intolerance, lipid changes, or mouth ulcers. Personalization is not optional with rapamycin.

Start timing depends on genotype and personal risk factors. Dr. Grant Fraser's general guidance from the Q&A is that APOE4/4 homozygotes may benefit from starting earlier given their elevated Alzheimer's risk, while 3/4 and 2/4 heterozygotes can weigh their other risk factors (family history, metabolic health, cardiovascular status) before starting. Timing rapamycin around workouts also matters, as mTOR inhibition can blunt muscle growth if taken too close to resistance training. Work with a physician experienced in rapamycin prescribing for APOE4 carriers who can personalize both the start decision and the dosing protocol.

Rapamycin at longevity doses is generally well tolerated but can cause mouth ulcers (canker sores), temporary lipid elevations (particularly LDL and triglycerides), glucose intolerance, and mild immunosuppression in some patients. The risk profile is dose-dependent, which is why Dr. Grant Fraser emphasizes blood-level monitoring rather than fixed doses. Most side effects resolve with dose adjustment. APOE4 carriers already monitoring ApoB and HOMA-IR should track these closely during the first few months of rapamycin to catch any metabolic shifts early.